Table 1 Description of the patient population by HER2 status prior to T-DXd treatment
HER2-0 (n = 21) | HER2-low (n = 44) | HER2-positive (n = 126) | Total (n = 191) | |
|---|---|---|---|---|
Median age at metastatic diagnosis, years (range) | 57.5 (25.4–76.5) | 52.6 (27.6–70.1) | 48.3 (21.4–78.0) | 50.9 (21.4–78.0) |
Sex | ||||
Female | 21 (100%) | 44 (100%) | 124 (98.4%) | 189 (99.0%) |
Male | 0 (0%) | 0 (0%) | 2 (1.6%) | 2 (1.0%) |
Race | ||||
African American | 1 (4.8%) | 2 (4.5%) | 15 (11.9%) | 18 (9.4%) |
Asian or Pacific Islander | 0 (0.0%) | 0 (0.0%) | 4 (3.2%) | 4 (2.1%) |
White | 20 (95.2%) | 39 (88.6%) | 101 (80.2%) | 160 (83.8%) |
Other | 0 (0.0%) | 2 (4.5%) | 5 (4.0%) | 7 (3.7%) |
Unknown | 0 (0.0%) | 1 (2.3%) | 1 (0.8%) | 2 (1.0%) |
Time from metastatic diagnosis to initiation of T-DXd, months (range) | 40 (11–110) | 45 (2–185) | 37.9 (-12–256) | 40 (-12–256) |
Median number of metastatic sites at diagnosis (range) | 3 (1–4) | 2 (1–7) | 2 (0–6) | 2 (0–7) |
Hormone receptor status at initiation of T-DXd | ||||
HR-positive | 12 (57.1%) | 30 (68.2%) | 67 (53.2%) | 109 (57.1%) |
HR-negative | 9 (42.9%) | 14 (31.8%) | 58 (46.0%) | 81 (42.4%) |
Not Done | 0 (0%) | 0 (0%) | 1 (0.8%) | 1 (0.5%) |
Prior lines of treatment in the advanced setting, median (range) | 4 (3–8) | 4.5 (0–12) | 4 (0–16) | 4 (0–16) |
Prior lines of chemotherapy, median (range) | 2 (1–4) | 2 (0–6) | 2 (0–9) | 2 (0–9) |
Prior lines of endocrine therapy, median (range) | 1 (0–4) | 2 (0–5) | 0 (0–5) | 0 (0–5) |
Treatment administered immediately after T-DXd* | ||||
Chemotherapy +/- anti-HER2 mAb | 5 (50%) | 11 (55%) | 21 (28%) | 37 (35.2%) |
HER2 TKI-containing regimen | 0 (0%) | 0 (0%) | 27 (36%) | 27 (25.7%) |
ADC (excluding T-DM1) | 3 (30%) | 3 (15%) | 4 (5.3%) | 10 (9.5%) |
T-DM1-containing regimen | 0 (0%) | 1 (5%) | 2 (2.7%) | 3 (2.9%) |
Immunotherapy-based regimen | 0 (0%) | 2 (10%) | 6 (8.0%) | 8 (7.6%) |
Other | 2 (20%) | 3 (15%) | 15 (20%) | 20 (19.1%) |
